Publication:
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

dc.contributor.authorBlanco, Gonzalo
dc.contributor.authorPuiggros, Anna
dc.contributor.authorBaliakas, Panagiotis
dc.contributor.authorAthanasiadou, Anastasia
dc.contributor.authorGarcia-Malo, MaDolores
dc.contributor.authorCollado, Rosa
dc.contributor.authorXochelli, Aliki
dc.contributor.authorRodriguez-Rivera, Maria
dc.contributor.authorOrtega, Margarita
dc.contributor.authorJose Calasanz, Ma
dc.contributor.authorLuno, Elisa
dc.contributor.authorVargas, MaTeresa
dc.contributor.authorGrau, Javier
dc.contributor.authorMartinez-Laperche, Carolina
dc.contributor.authorValiente, Alberto
dc.contributor.authorCervera, Jose
dc.contributor.authorAnagnostopoulos, Achilles
dc.contributor.authorGimeno, Eva
dc.contributor.authorAbella, Eugenia
dc.contributor.authorStalika, Evangelia
dc.contributor.authorMa Hernandez-Rivas, Jesus
dc.contributor.authorJose Ortuno, Francisco
dc.contributor.authorRobles, Diego
dc.contributor.authorFerrer, Ana
dc.contributor.authorIvars, David
dc.contributor.authorGonzalez, Marcos
dc.contributor.authorBosch, Francesc
dc.contributor.authorAbrisqueta, Pau
dc.contributor.authorStamatopoulos, Kostas
dc.contributor.authorEspinet, Blanca
dc.contributor.authoraffiliation[Blanco, Gonzalo] Hosp del Mar, Serv Patol, Lab Citol Hematol, Lab Citogenet Mol, Barcelona, Spain
dc.contributor.authoraffiliation[Puiggros, Anna] Hosp del Mar, Serv Patol, Lab Citol Hematol, Lab Citogenet Mol, Barcelona, Spain
dc.contributor.authoraffiliation[Rodriguez-Rivera, Maria] Hosp del Mar, Serv Patol, Lab Citol Hematol, Lab Citogenet Mol, Barcelona, Spain
dc.contributor.authoraffiliation[Ferrer, Ana] Hosp del Mar, Serv Patol, Lab Citol Hematol, Lab Citogenet Mol, Barcelona, Spain
dc.contributor.authoraffiliation[Espinet, Blanca] Hosp del Mar, Serv Patol, Lab Citol Hematol, Lab Citogenet Mol, Barcelona, Spain
dc.contributor.authoraffiliation[Blanco, Gonzalo] Hosp del Mar, IMIM, Canc Res Programme, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Puiggros, Anna] Hosp del Mar, IMIM, Canc Res Programme, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Rodriguez-Rivera, Maria] Hosp del Mar, IMIM, Canc Res Programme, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Ferrer, Ana] Hosp del Mar, IMIM, Canc Res Programme, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Espinet, Blanca] Hosp del Mar, IMIM, Canc Res Programme, Grp Recerca Translac Neoplasies Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Blanco, Gonzalo] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain
dc.contributor.authoraffiliation[Baliakas, Panagiotis] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden
dc.contributor.authoraffiliation[Xochelli, Aliki] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden
dc.contributor.authoraffiliation[Stamatopoulos, Kostas] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden
dc.contributor.authoraffiliation[Athanasiadou, Anastasia] G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece
dc.contributor.authoraffiliation[Anagnostopoulos, Achilles] G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece
dc.contributor.authoraffiliation[Stamatopoulos, Kostas] G Papanicolaou Hosp, Dept Hematol, Thessaloniki, Greece
dc.contributor.authoraffiliation[Athanasiadou, Anastasia] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
dc.contributor.authoraffiliation[Anagnostopoulos, Achilles] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
dc.contributor.authoraffiliation[Stamatopoulos, Kostas] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece
dc.contributor.authoraffiliation[Garcia-Malo, MaDolores] Hosp Univ Morales Meseguer, Serv Hematol, Murcia, Spain
dc.contributor.authoraffiliation[Jose Ortuno, Francisco] Hosp Univ Morales Meseguer, Serv Hematol, Murcia, Spain
dc.contributor.authoraffiliation[Collado, Rosa] Consorcio Hosp Gen Univ, Serv Hematol, Valencia, Spain
dc.contributor.authoraffiliation[Ivars, David] Consorcio Hosp Gen Univ, Serv Hematol, Valencia, Spain
dc.contributor.authoraffiliation[Xochelli, Aliki] CERTH, Inst Appl Biosci, Thessaloniki, Greece
dc.contributor.authoraffiliation[Stalika, Evangelia] CERTH, Inst Appl Biosci, Thessaloniki, Greece
dc.contributor.authoraffiliation[Stamatopoulos, Kostas] CERTH, Inst Appl Biosci, Thessaloniki, Greece
dc.contributor.authoraffiliation[Ortega, Margarita] Hosp Valle De Hebron, Lab Citogenet, Barcelona, Spain
dc.contributor.authoraffiliation[Bosch, Francesc] Hosp Valle De Hebron, Lab Citogenet, Barcelona, Spain
dc.contributor.authoraffiliation[Abrisqueta, Pau] Hosp Valle De Hebron, Lab Citogenet, Barcelona, Spain
dc.contributor.authoraffiliation[Ortega, Margarita] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Bosch, Francesc] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Abrisqueta, Pau] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Jose Calasanz, Ma] Univ Navarra, Dept Genet, Serv Citogenet, Pamplona, Spain
dc.contributor.authoraffiliation[Luno, Elisa] Hosp Univ Cent Asturias, Serv Hematol, Oviedo, Spain
dc.contributor.authoraffiliation[Vargas, MaTeresa] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, UGC Hematol, Seville, Spain
dc.contributor.authoraffiliation[Grau, Javier] Univ Autonoma Barcelona, Inst Recerca Leucemia Josep Carreras IJC, ICO Hosp Germans Trias & Pujol, Serv Hematol, Badalona, Spain
dc.contributor.authoraffiliation[Martinez-Laperche, Carolina] Hosp GU Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Serv Hematol, Lab Genet Hematol, Madrid, Spain
dc.contributor.authoraffiliation[Valiente, Alberto] Complejo Hospitalario Navarra, Serv Genet & Hematol, Pamplona, Spain
dc.contributor.authoraffiliation[Cervera, Jose] Hosp Univ La Fe, Unidad Genet, Valencia, Spain
dc.contributor.authoraffiliation[Gimeno, Eva] Hosp del Mar, Serv Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Abella, Eugenia] Hosp del Mar, Serv Hematol, Barcelona, Spain
dc.contributor.authoraffiliation[Ma Hernandez-Rivas, Jesus] Univ Salamanca, Hosp Univ Salamanca, Ctr Invest Canc, CSIC,Serv Hematol,IBSAL,IBMCC, Salamanca, Spain
dc.contributor.authoraffiliation[Gonzalez, Marcos] Univ Salamanca, Hosp Univ Salamanca, Ctr Invest Canc, CSIC,Serv Hematol,IBSAL,IBMCC, Salamanca, Spain
dc.contributor.authoraffiliation[Robles, Diego] Hosp Txagorritxu, Serv Hematol, Vitoria, Spain
dc.contributor.funderFEDER
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderSpanish Ministry of Economy and Competitiveness
dc.contributor.funderGeneralitat de Catalunya
dc.contributor.funderPla Director d'Oncologia de Catalunya (XBTC)
dc.contributor.funderFundacio La Caixa
dc.contributor.funderSwedish Cancer Society
dc.contributor.funderSwedish Research Council
dc.contributor.funderLion's Cancer Research Foundation
dc.contributor.funderSelander's Foundation, Uppsala
dc.contributor.funderEU
dc.date.accessioned2023-02-12T02:23:59Z
dc.date.available2023-02-12T02:23:59Z
dc.date.issued2016-12-06
dc.description.abstractPatients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P = 3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10- year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.
dc.identifier.doi10.18632/oncotarget.13106
dc.identifier.essn1949-2553
dc.identifier.unpaywallURLhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=13106&path%5B%5D=41543
dc.identifier.urihttp://hdl.handle.net/10668/19441
dc.identifier.wosID389877500066
dc.issue.number49
dc.journal.titleOncotarget
dc.journal.titleabbreviationOncotarget
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number80916-80924
dc.publisherImpact journals llc
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject17p deletion
dc.subjectCll
dc.subjectMutations
dc.subjectCytogenetics
dc.subjectProgression
dc.subjectGuidelines
dc.subjectDiagnosis
dc.subjectPredicts
dc.subjectGenes
dc.subjectFish
dc.titleKaryotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7
dc.wostypeArticle
dspace.entity.typePublication

Files